Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
Details : Lojuxta (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolemia ("HoFH").
Brand Name : Lojuxta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : Lomitapide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lomitapide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Medison Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
Details : Under the terms of the agreement, Medison Pharma will distribute Juxtapid® (lomitapide) in Canada and Lojuxta® (lomitapide) and Myalept® (metreleptin) in Israel.
Brand Name : Juxtapid
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 04, 2021
Lead Product(s) : Lomitapide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Medison Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Lomitapide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Amryt Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Amryt and Swixx Sign Distribution Deal for Lojuxta
Details : Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.
Brand Name : Lojuxta
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 19, 2020
Lead Product(s) : Lomitapide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Amryt Pharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?